Posted by Michael Wonder on 13 Dec 2019
Y-mAbs’ GD2-GD3 vaccine granted rare paediatric disease designation
12 December 2019 - Y-mAbs Therapeutics today announced that its GD2-GD3 vaccine has been granted a rare paediatric disease designation by the FDA for the treatment of neuroblastoma.
The GD2-GD3 vaccine was originally developed by researchers at Memorial Sloan Kettering, and licensed to MabVax Therapeutics, which sub-licensed the compound for the treatment of neuroblastoma to Y-mAbs in 2018. Upon approval by the FDA of the GD2-GD3 Vaccine, Y-mAbs may be eligible for a priority review voucher and will share 20% of the net income received from the potential sale of such PRV with MabVax.
The GD2-GD3 Vaccine is being tested in a single center clinical trial at MSK where children with neuroblastoma, who are in remission, are being treated with seven subcutaneous injections during a year to prevent relapse.
